Waldenström Macroglobulinemia | Tumor

Iopofosine I 131 Is Promising Across Waldenstrom’s Macroglobulinemia Types

July 24th 2024, 3:00pm

Article

Eighty percent of patients with relapsed or refractory Waldenstrom’s macroglobulinemia responded to treatment with iopofosine I 131, researchers found.

FDA Approves Easier-to-Swallow Imbruvica Formulation

February 29th 2024, 10:00pm

Article

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

FDA Gives Cancer Drug Updates, Prostate Cancer Trial Enrolls Patients

January 15th 2024, 4:00pm

Podcast

Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.

Novel Drug Shows 100% Disease Control Rate in WM

January 9th 2024, 4:00pm

Article

A small study of iopofosine I 131 in patients with pretreated Waldenstrom’s macroglobulinemia showed that the disease control rate was 100%.

FDA Lifts Partial Hold on Trial Investigating Emavusertib in Lymphoma

August 19th 2022, 7:00pm

Article

The FDA has allowed the manufacturer of emavusertib to continue a phase 1/2 study investigating effects of the treatment in patients with lymphoma.

FDA Grants Orphan Drug Designation to Novel CAR-T Cell Therapy to Treat Waldenstrom Macroglobulinemia, a Rare Type of Cancer

June 27th 2022, 9:00pm

Article

Treatment with the novel CAR-T cell therapy was associated with favorable efficacy and safety results in a group of patients with follicular lymphoma, including a few with Waldenstrom macroglobulinemia, according to findings from a study presented at a recent medical conference.

Brukinsa Continues to Outperform Imbruvica for MYD88-Mutant Waldenström Macroglobulinemia

June 10th 2022, 9:00pm

Article

Brukinsa, which was approved in September 2021, resulted in better ouctomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.

Trial for Waldenstrom’s Macroglobulinemia Treatment Will Continue, as Early Data Yields Promising Results

May 2nd 2022, 9:00pm

Article

The trial of CLR 131 (iopofosine) for relapsed/refractory Waldenstrom’s macroglobulinemia will continue, as the drug will be studied in an estimated 50 patients.

Third Full Dose of COVID-19 Vaccine Increases Antibody Response in Patients with Blood Cancers

December 23rd 2021, 8:00pm

Article

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

HGTV Star Hilary Farr Shares Breast Cancer Journey, ‘Pistol Annies’ Singer Finishes Treatment and More

December 17th 2021, 4:00pm

Article

From the story of HGTV’s “Love it or List it” co-host Hilary Farr’s cancer journey to “Pistol Annies” singer Ashley Monroe ringing the bell after finishing cancer treatment, here’s what’s happening in the cancer landscape this week.